Cargando…

Dose-dependent effects of siRNA-mediated inhibition of SCAP on PCSK9, LDLR, and plasma lipids in mouse and rhesus monkey

SREBP cleavage-activating protein (SCAP) is a key protein in the regulation of lipid metabolism and a potential target for treatment of dyslipidemia. SCAP is required for activation of the transcription factors SREBP-1 and -2. SREBPs regulate the expression of genes involved in fatty acid and choles...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jensen, Kristian K., Tadin-Strapps, Marija, Wang, Sheng-ping, Hubert, James, Kan, Yanqing, Ma, Yong, McLaren, David G., Previs, Stephen F., Herath, Kithsiri B., Mahsut, Ablatt, Liaw, Andy, Wang, Shubing, Stout, Steven J., Keohan, CarolAnn, Forrest, Gail, Coelho, David, Yendluri, Satya, Williams, Stephanie, Koser, Martin, Bartz, Steven, Akinsanya, Karen O., Pinto, Shirly
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society for Biochemistry and Molecular Biology 2016
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5321219/ https://www.ncbi.nlm.nih.gov/pubmed/27707816 http://dx.doi.org/10.1194/jlr.M071498

Ejemplares similares

PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells
por: Lagace, Thomas A.
Publicado: (2014)

PCSK9 Prosegment Chimera as Novel Inhibitors of LDLR Degradation
por: Luna Saavedra, Yascara Grisel, et al.
Publicado: (2013)

PCSK9/LDLR System and Rheumatoid Arthritis-Related Atherosclerosis
por: Arida, Aikaterini, et al.
Publicado: (2021)

The effect of PCSK9 immunization on the hepatic level of microRNAs associated with the PCSK9/LDLR pathway
por: Ataei, Sarina, et al.
Publicado: (2023)

Quercetin improves lipid metabolism via SCAP-SREBP2-LDLr signaling pathway in early stage diabetic nephropathy
por: Jiang, Xiyuan, et al.
Publicado: (2019)

Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal Domain
por: Poirier, Steve, et al.
Publicado: (2016)

The LDLR, APOB, and PCSK9 Variants of Index Patients with Familial Hypercholesterolemia in Russia
por: Meshkov, Alexey, et al.
Publicado: (2021)

Anti-Inflammatory Effects of Ang-(1-7) in Ameliorating HFD-Induced Renal Injury through LDLr-SREBP2-SCAP Pathway
por: Zheng, Yaning, et al.
Publicado: (2015)

In Silico Insights into Protein–Protein Interaction Disruptive Mutations in the PCSK9-LDLR Complex
por: Martin, William R., et al.
Publicado: (2020)

Whole exome sequencing of familial hypercholesterolaemia patients negative for LDLR/APOB/PCSK9 mutations
por: Futema, Marta, et al.
Publicado: (2014)

LDLR and PCSK9 Are Associated with the Presence of Antiphospholipid Antibodies and the Development of Thrombosis in aPLA Carriers
por: Ochoa, Eguzkine, et al.
Publicado: (2016)

A phenome-wide association study to discover pleiotropic effects of PCSK9, APOB, and LDLR
por: Safarova, Maya S., et al.
Publicado: (2019)

Genetic Variants of LDLR and PCSK9 Associated with Variations in Response to Antihypercholesterolemic Effects of Armolipid Plus with Berberine
por: De Castro-Orós, Isabel, et al.
Publicado: (2016)

A New Strategy for Rapidly Screening Natural Inhibitors Targeting the PCSK9/LDLR Interaction In Vitro
por: Li, Li, et al.
Publicado: (2018)

23,24-Dihydrocucurbitacin B promotes lipid clearance by dual transcriptional regulation of LDLR and PCSK9
por: Li, Hui-hui, et al.
Publicado: (2019)

Heterozygous Ldlr-Deficient Hamster as a Model to Evaluate the Efficacy of PCSK9 Antibody in Hyperlipidemia and Atherosclerosis
por: Wu, Yue, et al.
Publicado: (2019)

Asialoglycoprotein receptor 1 is a novel PCSK9-independent ligand of liver LDLR cleaved by furin
por: Susan-Resiga, Delia, et al.
Publicado: (2021)

Genetic Polymorphisms in LDLR, APOB, PCSK9 and Other Lipid Related Genes Associated with Familial Hypercholesterolemia in Malaysia
por: Lye, Say-Hean, et al.
Publicado: (2013)

Lunasin functionally enhances LDL uptake via inhibiting PCSK9 and enhancing LDLR expression in vitro and in vivo
por: Gu, Lili, et al.
Publicado: (2017)

Patients With LDLR and PCSK9 Gene Variants Experienced Higher Incidence of Cardiovascular Outcomes in Heterozygous Familial Hypercholesterolemia
por: Doi, Takahito, et al.
Publicado: (2021)

Caffeine blocks SREBP2-induced hepatic PCSK9 expression to enhance LDLR-mediated cholesterol clearance
por: Lebeau, Paul F., et al.
Publicado: (2022)

Testosterone Deficiency Promotes Hypercholesteremia and Attenuates Cholesterol Liver Uptake via AR/PCSK9/LDLR Pathways
por: Yuefeng, Yu, et al.
Publicado: (2022)

Molecular interactions of PCSK9 with an inhibitory nanobody, CAP1 and HLA-C: Functional regulation of LDLR levels
por: Fruchart Gaillard, Carole, et al.
Publicado: (2022)

Allicin and Capsaicin Ameliorated Hypercholesterolemia by Upregulating LDLR and Downregulating PCSK9 Expression in HepG2 Cells
por: Nawaka, Nantiya, et al.
Publicado: (2022)

The cellular function of SCAP in metabolic signaling
por: Lee, Sun Hee, et al.
Publicado: (2020)

c-IAP1 Binds and Processes PCSK9 Protein: Linking the c-IAP1 in a TNF-α Pathway to PCSK9-Mediated LDLR Degradation Pathway
por: Xu, Weiming, et al.
Publicado: (2012)

A Locked Nucleic Acid Antisense Oligonucleotide (LNA) Silences PCSK9 and Enhances LDLR Expression In Vitro and In Vivo
por: Gupta, Nidhi, et al.
Publicado: (2010)

Potentiating CD8(+) T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signaling
por: Yuan, Juanjuan, et al.
Publicado: (2021)

Mutational Spectrum of LDLR and PCSK9 Genes Identified in Iranian Patients With Premature Coronary Artery Disease and Familial Hypercholesterolemia
por: Moradi, Arman, et al.
Publicado: (2021)

NMR, LC-MS Characterization of Rydingia michauxii Extracts, Identification of Natural Products Acting as Modulators of LDLR and PCSK9
por: Sut, Stefania, et al.
Publicado: (2022)

The Modulation of PCSK9 and LDLR by Supercritical CO(2) Extracts of Mentha longifolia and Isolated Piperitone Oxide, an In Vitro Study
por: Sut, Stefania, et al.
Publicado: (2021)

Blood lipid-related low-frequency variants in LDLR and PCSK9 are associated with onset age and risk of myocardial infarction in Japanese
por: Tajima, Tomoyuki, et al.
Publicado: (2018)

Correction to: Potentiating CD8(+) T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signaling
por: Yuan, Juanjuan, et al.
Publicado: (2021)

Oxidative Stress and Lipid Accumulation Augments Cell Death in LDLR-Deficient RPE Cells and Ldlr (−/−) Mice
por: Sreekumar, Parameswaran Gangadharan, et al.
Publicado: (2022)

The Sirt1 activator SRT3025 provides atheroprotection in Apoe(−/−) mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression
por: Miranda, Melroy X., et al.
Publicado: (2015)

17β-Estradiol Inhibits PCSK9-Mediated LDLR Degradation Through GPER/PLC Activation in HepG2 Cells
por: Fu, Wei, et al.
Publicado: (2020)

Genetic associations between serum low LDL-cholesterol levels and variants in LDLR, APOB, PCSK9 and LDLRAP1 in African populations
por: Hayat, Mahtaab, et al.
Publicado: (2020)

Silencing YY1 Alleviates Ox-LDL-Induced Inflammation and Lipid Accumulation in Macrophages through Regulation of PCSK9/ LDLR Signaling
por: Qian, Zhengyao, et al.
Publicado: (2022)

The SCAP/SREBP Pathway: A Mediator of Hepatic Steatosis
por: Moon, Young-Ah
Publicado: (2017)

Correction: Genetic associations between serum low LDL-cholesterol levels and variants in LDLR, APOB, PCSK9 and LDLRAP1 in African populations
por: Hayat, Mahtaab, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bp2nav83hj178mejdagemo6hgr